OTLK stock forecast
Our latest prediction for Outlook Therapeutics Inc's stock price was made on the Dec. 6, 2021 when the stock price was at 1.37$.
In the short term (2weeks), OTLK's stock price should outperform the market by 4.32%. During that period the price should oscillate between -11.14% and +25.89%.
In the medium term (3months), OTLK's stock price should outperform the market by 12.25%. During that period the price should oscillate between -48.03% and +60.66%.
Get email alertsCreate a solid portfolio with OTLK
About Outlook Therapeutics Inc
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.
At the moment the company generates 8M USD in revenues.
On its last earning announcement, the company reported a loss of -0.25$ per share.
The book value per share is -0.23$
Three months stock forecastDec. 6, 2021
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8M | - | -48M | -307.20% | -50M | -0.25 | - | - | 141M | -0.23 | -57M | - | -57M |